ACP
NAMS icon

Acuta Capital Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Acuta Capital Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$1.28M – 40
2024
Q4 		$1.28M Buy
+50,000
New +$1.06M 1.29% 25
2024
Q3 		– Sell
-22,500
Closed -$432K – 44
2024
Q2 		$432K Buy
+22,500
New +$451K 0.36% 29

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Acuta Capital Partners's NAMS Position: Q1 2025 in Review

Acuta Capital Partners sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 50,000 shares — an estimated $1.28M sold.

Acuta Capital Partners first reported a position in NAMS in Q2 2024 and held it in 2 quarters. The position peaked at $1.28M in Q4 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Acuta Capital Partners reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 50,000 NewAmsterdam Pharma shares in Q1 2025, an estimated $1.28M.
  • Acuta Capital Partners first reported a position in NewAmsterdam Pharma in Q2 2024 and held it in 2 quarters.
  • Acuta Capital Partners's NewAmsterdam Pharma position peaked at $1.28M in Q4 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.